Milwaukee, WI – According to filings with the U.S. Securities and Exchange Commission, Promentis Pharmaceuticals is raising $6,000,000.00 in new funding. Sources indicate as part of senior management President, Daniel Lawton played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company is developing innovative therapies for neuropsychiatric disorders. The Company’s first indication is trichotillomania, a highly prevalent disorder for which there is no approved therapy. Alterations in glutamate signaling within brain regions implicated in urge control and executive function have been proposed to contribute to the underlying pathology of trichotillomania, as well as other obsessive-compulsive and addictive disorders, and other CNS conditions.

To learn more about Promentis Pharmaceuticals, visit http://www.promentispharma.com/

Contact:
Daniel Lawton, President
414-238-2992
dlawton@promentispharma.com
https://www.linkedin.com/in/daniel-lawton-26520b86/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved